mRNA vaccines: The future of prevention of viral infections?

P Rzymski, A Szuster‐Ciesielska… - Journal of medical …, 2023 - Wiley Online Library
Messenger RNA (mRNA) vaccines against COVID‐19 are the first authorized biological
preparations developed using this platform. During the pandemic, their administration has …

mRNA vaccines against respiratory viruses

JA Whitaker, HM El Sahly… - Current Opinion in …, 2023 - journals.lww.com
mRNA vaccines against respiratory viruses : Current Opinion in Infectious Diseases mRNA
vaccines against respiratory viruses : Current Opinion in Infectious Diseases Log in or Register …

[HTML][HTML] Effectiveness of monovalent and bivalent mRNA vaccines in preventing COVID-19–associated emergency department and urgent care encounters among …

R Link-Gelles - MMWR. Morbidity and mortality weekly report, 2023 - cdc.gov
Abstract On June 19, 2022, the original monovalent mRNA COVID-19 vaccines were
approved as a primary series for children aged 6 months–4 years (Pfizer-BioNTech) and 6 …

Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

F Zhu, S Huang, X Liu, Q Chen, C Zhuang… - The Lancet …, 2023 - thelancet.com
Background The live-attenuated influenza virus vector-based intranasal SARS-CoV-2
vaccine (dNS1-RBD, Pneucolin; Beijing Wantai Biological Pharmacy Enterprise, Beijing …

Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases

LR Baden, HM El Sahly, B Essink, D Follmann… - Nature …, 2024 - nature.com
Abstract Primary vaccination with mRNA-1273 (100-µg) was safe and efficacious at
preventing coronavirus disease 2019 (COVID-19) in the previously reported, blinded Part A …

Maternal third dose of BNT162b2 mRNA vaccine and risk of infant COVID-19 hospitalization

M Lipschuetz, J Guedalia, SM Cohen, Y Sompolinsky… - Nature Medicine, 2023 - nature.com
Infants are at a higher risk of Coronavirus Disease 2019 (COVID-19)-related hospitalizations
compared to older children. In this study, we investigated the effect of the recommended …

[HTML][HTML] Preliminary estimates of effectiveness of monovalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection among children aged 3–5 years …

KE Fleming-Dutra - MMWR. Morbidity and mortality weekly report, 2023 - cdc.gov
Since June 2022, COVID-19 primary series vaccination has been recommended for young
children with either Moderna for children aged 6 months–5 years or Pfizer-BioNTech for …

Mpox virus mRNA-lipid nanoparticle vaccine candidates evoke antibody responses and drive protection against the Vaccinia virus challenge in mice

H Xia, YR He, XY Zhan, GF Zha - Antiviral Research, 2023 - Elsevier
In response to the human Mpox (hMPX) epidemic that began in 2022, there is an urgent
need for a monkeypox vaccine. Here, we have developed a series of mRNA-lipid …

[HTML][HTML] Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA …

DY Lin, Y Xu, Y Gu, D Zeng, B Wheeler… - The Lancet Infectious …, 2023 - thelancet.com
Background Data on the protection conferred by COVID-19 vaccination and previous SARS-
CoV-2 infection against omicron (B. 1.1. 529) infection in young children are scarce. We …

Emerging and re-emerging pediatric viral diseases: a continuing global challenge

SA Hoffman, YA Maldonado - Pediatric Research, 2024 - nature.com
The twenty-first century has been marked by a surge in viral epidemics and pandemics,
highlighting the global health challenge posed by emerging and re-emerging pediatric viral …